Indications for TAZICEF:
Susceptible infections including lower respiratory tract (eg, pneumonia), skin and skin structure, UTIs, septicemia, bone and joint, gynecologic (eg, endometritis, pelvic cellulitis), meningitis, intraabdominal (eg, peritonitis).
Administer in upper outer quadrant of the gluteus maximus or lateral part of the thigh. Usual dose: 1g IV or IM every 8–12 hours. Uncomplicated UTIs: 250mg IV or IM every 12 hours. Complicated UTIs: 500mg IV or IM every 8–12 hours. Bone and joint: 2g IV every 12 hours. Uncomplicated pneumonia, mild skin and skin structure: 500mg–1g IV or IM every 8 hours. Serious gynecologic, intraabdominal, meningitis, or very severe life threatening (eg, immunocompromised): 2g IV every 8 hours. Lung infections: 30–50mg/kg IV every 8 hours; max of 6g/day. Renal dysfunction: CrCl 31–50mL/min: 1g every 12 hours; CrCl 16–30mL/min: 1g every 24 hours; CrCl 6–15mL/min: 500mg every 24 hours; CrCl <5mL/min: 500mg every 48 hours. Hemodialysis: 1g loading dose then 1g after each dialysis session. Peritoneal dialysis: 1g loading dose then 500mg every 24 hours.
Neonates: 30mg/kg IV every 12 hours. 1 month-12 years: 30–50mg/kg IV every 8 hours, max of 6g/day. Renal impairment: reduce dose.
Penicillin or other allergy. Renal or hepatic impairment, poor nutritional state, long term use: monitor prothrombin time. GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.
Nephrotoxicity with concomitant aminoglycosides, diuretics (eg, furosemide). Antagonized by chloramphenicol. False (+) glucose test with Clinitest, Benedict's, or Fehling's soln.
Hypersensitivity reactions (eg, rash, pruritus, fever), local reactions, GI upset, elevated liver enzymes.
Vials 1g—1, 10, 25